BiVictriX Therapeutics PLC Director Dealing (5534R)

TIDMBVX

RNS Number : 5534R

BiVictriX Therapeutics PLC

08 November 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Director Dealing

Alderley Park, 8 November 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces the following dealings in the Company's ordinary shares of 1 pence each ("Ordinary Shares").

Professor Robert Hawkins, a Non--Executive Director of the Company, has purchased 100,000 Ordinary Shares via four transactions which are summarised in the table below:

 
 Date of transaction    Number of Ordinary   Price per Ordinary 
                         Shares purchased     Share 
 2 November 2021        35,000               21.9p 
                       -------------------  ------------------- 
 3 November 2021        15,000               23p 
                       -------------------  ------------------- 
 3 November 2021        30,000               24.625p 
                       -------------------  ------------------- 
 4 November 2021        20,000               22.44p 
                       -------------------  ------------------- 
 

Following these transactions, Professor Hawkins is beneficially interested in 225,000 Ordinary Shares, representing 0.34% of the Company's total issued share capital.

**Ends**

 
   For more information, please contact: 
     BiVictriX Therapeutics plc 
     Tiffany Thorn, Chief Executive Officer    Email: [e-mail] 
      Iain Ross, Chairman 
 
     SP Angel Corporate Finance LLP (NOMAD 
      and Broker)                               Tel: [phone] 
                                                0470 
     David Hignell, Caroline Rowe (Corporate 
      Finance) 
      Vadim Alexandre, Rob Rees (Sales and 
      Broking) 
     Panmure Gordon (UK) Limited (Joint        Tel: [phone] 
      Broker)                                   2500 
     Rupert Dearden/Freddy Crossley/Emma 
      Earl 
      Consilium Strategic Communications 
     Ashley Tapp, Suki Virji, Priit Piip       Tel: [phone] 
                                                Email: [e-mail] 
 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni(R) therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Robert Hawkins 
     -------------------------------  -------------------------------------- 
 2.   Reason for the Notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Non-Executive Director 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             BiVictriX Therapeutics plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              213800ZI85IZNA6N3L53 
     -------------------------------  -------------------------------------- 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description                      Ordinary Shares of 1 pence each 
       of the Financial                 GB00BNXH3K91 
       instrument, 
       type of instrument 
      Identification 
       code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the                    Purchase of 100,000 Ordinary 
       transactions                     Shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and                       Price(s)                 Volume(s) 
       volume(s)                                     1. 21.9p      35,000 
                                                                    15,000 
                                                      2. 23p        30,000 
                                                                    20,000 
 
                                                      3. 24.625p 
 
                                                      4. 22.44p 
                                                                  ---------- 
     -------------------------------  -------------------------------------- 
 d)        Aggregated                   Price(s)            Volume(s) 
            information:                 22.99p (weighted 
             *    Aggregated volume       average)           100,000 
                                                            ---------- 
 
             *    Price 
     -------------------------------  -------------------------------------- 
 e)   Date of the                       2 - 4 November 2021 
       transactions 
     -------------------------------  -------------------------------------- 
 f)   Place of the                     AIM, London Stock Exchange 
       transactions 
     -------------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFZMGMVKZGMZM

(END) Dow Jones Newswires

November 08, 2021 02:00 ET (07:00 GMT)